Ascierto PA, Tang H, Dolfi S, Nyakas M, Marie Svane I, Muñoz-Couselo E, Grob JJ, Gomez-Roca CA, Chiarion-Sileni V, Peltola K, Larkin J, Melero I, Callahan M, Dummer R, Djidel P, Warad D, Reusser-Wolf D, Lipson EJ, Garnett-Benson C(2025) Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020 J Immunother Cancer, 13(2) DOI 10.1136/jitc-2024-009773, PubMed 40010775
Bregni G, Adams R, Bale R, Bali MA, Bargellini I, Blomqvist L, Brown G, Cremolini C, Demetter P, Denecke T, Dohan A, Dopazo C, Elez E, Evrard S, Feakins R, Guckenberger M, Guren MG, Hawkins M, Hoorens A, Huguet E, Intven M, Koessler T, Kunz WG, Lordick F, Lucidi Vet al.(2025) EORTC consensus recommendations on the optimal management of colorectal cancer liver metastases Cancer Treat Rev, 136, 102926 DOI 10.1016/j.ctrv.2025.102926, PubMed 40179590
Chen IM, Johansen JS, Theile S, Silverman LM, Pelz KR, Madsen K, Dajani O, Lim KZM, Lorentzen T, Gaafer O, Koniaris LG, Ferreira AC, Neelon B, Guttridge DC, Ostrowski MC, Zimmers TA, Nielsen D(2025) Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia J Clin Oncol, JCO2301965(in press) DOI 10.1200/JCO.23.01965, PubMed 40354592
